Thursday, September 24, 2026

HomeHealth NewsRituximab not superior to conventional strategy for eosinophilic granulomatosis with polyangiitis

Rituximab not superior to conventional strategy for eosinophilic granulomatosis with polyangiitis

- Advertisement -

For patients with eosinophilic granulomatosis with polyangiitis (EGPA), rituximab is not superior to the conventional remission induction strategy, according to a study published online July 29 in the Annals of Internal Medicine.

Click here to view the original article.

- Advertisment -
- Advertisement -

Recently Viewed